{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-002245","form_type":"8-K","ticker":"NEUP","cik":"0001191070","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.650497+00:00","generated_at":"2026-05-16T11:10:29.581329+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CEO Spyridon Papapetropoulos transitions to interim CEO under consulting agreement","bullets":["Employment terminated Dec 31, 2025; Papapetropoulos remains on Board of Directors.","Consulting agreement effective Jan 1, 2026; $800/hr for up to ~40 hours/month.","Agreement terminates upon consummation of strategic transaction or after 12 months.","Severance includes annual base salary, target bonus, and medical premiums under prior employment agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-002245","json":"https://secwatch.observer/filing/0001213900-26-002245.json","markdown":"https://secwatch.observer/filing/0001213900-26-002245.md","text":"https://secwatch.observer/filing/0001213900-26-002245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1191070/000121390026002245/0001213900-26-002245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1191070/000121390026002245/ea0272154-8k_neuphoria.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:10:29.581329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}